Affinity Asset Advisors’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Affinity Asset Advisors’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-225,000	Closed	-$29.6M	–	91
2020 Q4	$29.6M	Buy	+225,000	New	+$19.9M	15.69%	1

Affinity Asset Advisors's EIDX Position: Q1 2021 in Review

Affinity Asset Advisors sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 225,000 shares — an estimated $29.6M sold.

Affinity Asset Advisors first reported a position in EIDX in Q4 2020 and held it in 1 quarter. The position peaked at $29.6M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Affinity Asset Advisors reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Affinity Asset Advisors sold 225,000 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $29.6M.
Affinity Asset Advisors first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Affinity Asset Advisors's Eidos Therapeutics, Inc. Common Stock position peaked at $29.6M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Affinity Asset Advisors's 13F filing for Q1 2021, filed 14 May 2021.